Fragment 176-191

Growth hormone has a fat side and a sugar side. It pushes fat cells to give up stored fuel, especially during fasting and exercise. It also works against insulin, which is why people with too much growth hormone can develop high blood sugar. In the whole hormone, those two effects arrive as a bundle.

That bundle is what made the tail of the molecule interesting. If the fat effects lived in one region and the sugar effects in another, a short synthetic piece might deliver one without the other. A group that included Frank Ng, later at Monash University in Australia, spent years testing that idea with pieces of different lengths.

Their 1978 results showed how fussy this region is. Pieces covering residues 172, 176, 177 or 178 through 191 all moved blood sugar and insulin. Pieces starting at 179 or 180 did nothing in the tests used. A single dose of the peptides containing residues 178 to 191 made rats less sensitive to insulin. The authors concluded that the active pieces needed both the right sequence and the right physical shape.¹²

Fat cells balance two jobs all day, building fat for storage and breaking it down for fuel. Growth hormone acts on both. In 1993 the Monash group gave the 177 to 191 piece to rats and measured their fat tissue. It blocked fat production as strongly as the whole hormone, and it did not significantly speed fat release, measured as glycerol coming out of the fat.

That led the authors to suggest that growth hormone’s main effect on fat works at the building stage. Their later studies told a fuller story. By 2000 the same group reported that the 177 to 191 piece, then called AOD9401, switched on hormone-sensitive lipase, the enzyme that releases stored fat, and switched off acetyl CoA carboxylase, which builds new fat.

In obese Zucker rats treated for 20 days, AOD9401 slowed weight gain and shrank fat cells, and unlike growth hormone it did not cause insulin resistance or glucose intolerance. That result describes a piece starting at residue 177, given for weeks. The 1978 blood sugar data came from single doses that included the 176 piece itself. Short-term and long-term effects can differ, and the two sets of experiments never tested the same molecule in the same way.²³¹

Sellers promote Fragment 176-191 for fat loss, and a 2026 critical review of peptides in sport lists it among synthetic fragments marketed for fat metabolism. The research behind that claim is narrow. It amounts to a handful of rat and tissue studies published between 1978 and 2001, most of them on neighboring pieces rather than on the 176 to 191 sequence itself.

What those studies support is a short list. Pieces from this region slowed fat building in rat fat tissue. A related piece slowed weight gain in obese rats, and a modified version slowed weight gain in obese mice while raising fat burning. Beyond fat and blood sugar, the studies cited here only add receptor, cell-growth and breakdown chemistry for AOD-9604.

None of the studies or reviews cited here describes a human trial of Fragment 176-191. Every human data point near this molecule comes from AOD-9604, its close relative, and that program did not succeed. A 2026 review of growth hormone-axis peptides rates AOD-9604 tier B/C, limited human data. The natural fragment, with only rat data behind it, has less.⁵²³⁸⁶

Line the two molecules up and they differ by a single letter. In human growth hormone, residue 176 is phenylalanine. AOD-9604, the drug candidate, is residues 177 to 191 with a tyrosine added at the front. So natural Fragment 176-191 and AOD-9604 are the same length, share 15 of 16 amino acids, and differ only at the first position.

Labels make that difference harder to see. A 2026 clinical review notes that AOD-9604 is sometimes labeled hGH 176-191 because of the added tyrosine. A vial sold as Fragment 176-191 might hold the natural sequence or AOD-9604. Given what testing of gray-market peptides has found, it might also hold something else.

Does one amino acid matter? In this region it can. The 1978 experiments found that peptides starting at residue 178 changed insulin sensitivity while a peptide starting at residue 179 was inert, a one-residue shift that switched the activity off. Tyrosine and phenylalanine are chemically similar, so this particular swap may be minor, but none of the studies here compares the two head to head.

This is why evidence for one cannot simply be borrowed by the other. The human trial data, the oral studies and the blood sugar sparing results belong to AOD-9604 and its 177 to 191 parent. The earliest blood sugar warning includes the natural 176 to 191 sequence. Whenever you see a claim about Fragment 176-191, the first useful question is which molecule the study actually used.⁹⁴⁶⁵¹³

Short peptides tend to be broken down quickly, and the one lab study of this family points the same way. In a study published in 2015, scientists at a US anti-doping laboratory incubated AOD-9604, the close relative of Fragment 176-191, in human serum and urine to see how it breaks down. They found six possible breakdown products, and the parent peptide proved less durable than one of its own fragments.

One piece outlasted the rest. A nine-amino-acid stretch, CRSVEGSCG, was significantly more stable than the parent or any other breakdown product. It spans the two cysteines near the end of the chain, the same stretch that sits inside both AOD-9604 and the natural 176 to 191 sequence. For anti-doping labs, that durable core is useful, because screening for it may extend the window in which use is detected.

For anyone reading claims about the fragment, the finding raises a fair question. If most of the injected peptide is quickly cut into smaller pieces, which piece does the work, and for how long? Nobody has answered that for Fragment 176-191 in people. The 1978 rat study adds a further hint, since its authors concluded that activity depended on the right physical shape as well as the right sequence, and a chopped fragment may lose that shape.

This is the honest edge of the science. The breakdown study used AOD-9604 in a dish and measured chemistry alone, and nobody has tracked the natural fragment in a person. It still explains why online claims about how long the fragment keeps working rest on guesswork rather than measurement.⁴¹

The closest thing to a human test of Fragment 176-191 is the AOD-9604 obesity program. Phase 2a trials of AOD-9604 were underway by early 2002. A later 24-week trial of a form taken by mouth enrolled 534 people, randomized 502 and failed to show a significant benefit on its primary weight-loss endpoint, according to a 2026 review that relies on the sponsor’s reported outcomes.

The same review describes AOD-9604 as generally well tolerated in people, with no meaningful rise in IGF-1 and no significant change in glucose tolerance. The safety design seemed to translate from animals to humans. The fat loss did not. For a fat-loss peptide, that is the result that matters, and it is the only large human result among the studies cited here.

Nothing comparable appears for the natural 176 to 191 sequence. None of the sources here describes a human safety study, a dose-finding study or an efficacy trial. Anyone taking it is running an experiment that the original researchers never ran, without the monitoring, the purity checks or the comparison group that would let them learn anything from it.⁷⁶

With no human studies, the safety picture rests on the animal data and on what is known about the supply. The animal data include a warning. In normal rats, the 176 to 191 piece raised blood sugar briefly and insulin for longer, and closely related pieces reduced insulin sensitivity after a single dose.

That matters most for anyone with prediabetes, diabetes or insulin resistance, and for anyone taking glucose-lowering medicine. A 2026 review of peptide use in sport and bodybuilding lists insulin resistance and dyslipidemia, an unhealthy shift in blood fats, among the emerging risks for this class of compounds.

The supply is the other risk. The same review describes an unregulated supply chain in which products are often mislabeled or contaminated. A peptide injected under the skin bypasses the gut’s defenses, so sterility matters as much as identity.

Talk to a clinician first if you are pregnant or breastfeeding, have a history of cancer, live with a metabolic condition, or compete in tested sport. Anyone already taking insulin or other glucose-lowering medicine should be especially careful, given the rat data on insulin.¹⁵

Fragment 176-191’s own history points to the markers that matter. If molecules from this region can push insulin up, the honest way to know what is happening in your body is to measure it. Fasting glucose and fasting insulin, read together, help a clinician estimate how hard your body works to hold blood sugar steady. They are a clue to insulin resistance, not a diagnosis on their own.

HbA1c shows your average blood sugar across roughly three months, which smooths out the noise of any single morning. ALT, a liver enzyme, flags stress on the liver and is often raised in fatty liver, a condition that travels with insulin resistance.

Vitals Vault does not offer Fragment 176-191. These markers give a clinician baseline metabolic context, chosen around your own risks, and a retest shows how that metabolic picture moves. Body composition itself needs its own measurement.¹

Fragment 176-191 is not an FDA-approved drug, and it does not appear on FDA’s compounding safety page, current as of April 22, 2026. Products sold online with a research-use label are not made for people, and their contents are not checked before sale.

In sport the answer is simpler. The World Anti-Doping Agency prohibits growth hormone fragments at all times and names hGH 176-191 as an example, so tested athletes should treat it as banned.¹⁰¹¹⁵

Fragment 176-191 is a 16-amino-acid copy of growth hormone’s tail, one letter away from a drug candidate that failed its human obesity trial. Its own record is a few rat studies, and the first of them showed a rise in blood sugar and insulin. The fat-tissue results that made the region famous came mostly from neighboring pieces, and the only large human trial in the family tested a different molecule and missed its goal.

The biology is still interesting. Growth hormone does carry a fat-regulating region near its tail, and the Monash work mapped it carefully. But a molecule with no human trials, a muddled name and a blood sugar warning in its first paper needs more than a mechanism. If you are drawn to it, the next question worth asking is what you hope it will do that a measured plan for insulin, sleep and muscle would not.¹²⁶